WEP Clinical LTD (WEP), a specialist services company that works with drug developers to help patients and physicians gain early access to medicines when no other treatment options are available, has partnered with Japan-based Global Specialty Pharmaceutical company, Kyowa Kirin, to launch a Post-Approval Named Patient Program (PA-NPP) for POTELIGEO® (mogamulizumab), a treatment for adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS).
The PA-NPP is designed to ensure that physicians in the following countries in the Asia Pacific region – Bangladesh, Bhutan, Brunei, Cambodia, Hong Kong, India, Indonesia, Laos, Macau, Malaysia, Myanmar, Nepal, New Zealand, Papua New Guinea, Palau, Philippines, Singapore, Sri Lanka, Taiwan, Thailand, Timor-Leste, and Vietnam – where the product is not currently commercially available, can request POTELIGEO® on behalf of individual adult MF/SS patients who have received at least one prior systemic therapy.
Jas Khera, Managing Director of WEP, said:
“We are excited to partner with Kyowa Kirin to provide access to POTELIGEO® through this PA-NPP. This program will help ensure that patients in several countries in the Asia Pacific region have a much-needed treatment option available to them, and we are proud to be a part of such an effort.”
For physicians who are interested in further information on the POTELIGEO® PA-NPP, please contact: poteligeonpp@wepclinical.com.
About WEP
At WEP Clinical, we are With Every Patient, as we believe every patient should have access to treatment! With this as our guiding principle, we have created a market leading, solutions driven, healthcare services company that partners with drug developers to create broader treatment access solutions for patients worldwide. We take pride in the high-quality output and positive customer experience we create while delivering our services. We specialize in the following: Expanded Access and Post-Approval Named Patient Programs; Market Access Solutions; Home Nursing Services for Decentralized Clinical Trials; and Clinical Trial Sourcing. For more information, please visit www.wepclinical.com.
About Kyowa Kirin
Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a heritage of more than 70 years, the company applies cutting-edge science, including expertise in antibody research and engineering, to address the needs of patients across multiple therapeutic areas such as nephrology, oncology, immunology/allergy and neurology. Across its four regions – Japan, Asia Pacific, North America and EMEA/International – Kyowa Kirin focuses on its purpose, to make people smile, and is united by its shared values of commitment to life, teamwork, innovation and integrity. Learn more about the Company at www.kyowakirin.com.
About POTELIGEO® (mogamulizumab)
POTELIGEO® is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4), which is frequently expressed on leukemic cells of certain haematologic malignancies including cutaneous T-cell lymphoma (CTCL). POTELIGEO® uses Kyowa Kirin’s proprietary POTELLIGENT® technology, which enhances antibody-dependent cellular cytotoxicity (ADCC).
In August 2018, POTELIGEO® was approved in the U.S. for the treatment of adult patients with relapsed or refractory MF or SS after at least one prior systemic therapy.
The European Commission (EC) granted marketing authorisation for POTELIGEO® in November 2018 for the treatment of adult patients with MF or SS who have received at least one prior systemic therapy.
